SCHEDULE 13G: Deep Track Capital Discloses 9.99% Stake in COMPASS Pathways plc

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a 9.99% beneficial ownership stake in COMPASS Pathways plc, totaling 9,274,589 American Depositary Shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 9,274,589 American Depositary Shares (ADS) of COMPASS Pathways plc.
• This ownership represents 9.99% of the total outstanding shares of COMPASS Pathways plc, calculated based on 92,838,737 shares.
• The calculation of the percentage includes 92,423,796 Ordinary Shares outstanding as of January 10, 2025, and an additional 414,941 Ordinary Shares that would be converted by the reporting person up to the maximum percentage.
• The beneficially owned shares include 8,700,000 Pre-Funded Warrants and 17,559,648 Warrants exercisable into common shares, subject to a 9.99% maximum exercise limitation.
• The filing, a Schedule 13G, indicates a passive investment purpose, certifying that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable investment firm like Deep Track Capital is generally a positive signal, indicating investor confidence. The 9.99% stake is substantial, suggesting a strong belief in the company's long-term prospects without an intent to influence control.

Positives

• A significant institutional investor, Deep Track Capital, has taken a substantial 9.99% stake in COMPASS Pathways plc, indicating strong confidence in the company's prospects.
• The investment is declared as passive, suggesting a long-term investment horizon rather than an activist agenda, which can provide stability.

Risks

• The beneficial ownership includes a substantial number of warrants (8,700,000 Pre-Funded Warrants and 17,559,648 Warrants), which, if fully exercised, could lead to dilution for existing shareholders, although subject to a 9.99% maximum percentage exercise limitation.

Future Outlook

The filing itself does not provide forward-looking statements or guidance from the issuer, but rather discloses a current ownership stake by an institutional investor, reflecting their current investment position.

Management Comments

• David Kroin, Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and Director for Deep Track Biotechnology Master Fund, Ltd., certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This Schedule 13G filing indicates a significant investment by a specialized biotechnology fund in COMPASS Pathways plc, a company likely operating in the biotechnology or pharmaceutical sector. Such an investment suggests that Deep Track Capital sees value or potential in COMPASS Pathways plc's business model or pipeline, aligning with broader trends of institutional interest in innovative healthcare and biotech companies, particularly those with novel therapeutic approaches.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports a passive ownership stake and does not contain performance metrics for direct comparison to industry standards.
• However, the acquisition of a near 10% stake by a specialized biotechnology fund like Deep Track Capital is a notable event, suggesting a strong conviction in COMPASS Pathways plc's prospects within the biotech industry.
• This type of significant, passive institutional investment is common in the biotech sector, where specialized funds often take substantial positions in companies with promising drug pipelines or technologies, similar to how funds might invest in early-stage or growth-phase biopharmaceutical companies like Moderna (MRNA) or BioNTech (BNTX) during their development, or smaller, innovative firms exploring new therapeutic modalities.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a large stake could be viewed positively, potentially boosting investor confidence and market perception of the company's value.

Next Steps

• The document does not specify future actions or milestones for COMPASS Pathways plc. It is a disclosure of current ownership by an investor.

Key Dates

Recommendation

Keywords

COMPASS Pathways plc, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, beneficial ownership, American Depositary Shares, ADS, biotechnology, pharmaceuticals, investment, institutional investor, warrants